189 related articles for article (PubMed ID: 31412155)
1. Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report.
Wu J; Chen Y; Hageman L; Francisco L; Ness EC; Parman M; Kung M; Watson JA; Weisdorf DJ; Snyder DS; McGlave PB; Forman SJ; Arora M; Armenian SH; Bhatia R; Bhatia S
Cancer; 2019 Nov; 125(22):4033-4042. PubMed ID: 31412155
[TBL] [Abstract][Full Text] [Related]
2. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
[TBL] [Abstract][Full Text] [Related]
3. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry.
Socié G; Stone JV; Wingard JR; Weisdorf D; Henslee-Downey PJ; Bredeson C; Cahn JY; Passweg JR; Rowlings PA; Schouten HC; Kolb HJ; Klein JP
N Engl J Med; 1999 Jul; 341(1):14-21. PubMed ID: 10387937
[TBL] [Abstract][Full Text] [Related]
5. Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective.
Enright H; Davies SM; DeFor T; Shu X; Weisdorf D; Miller W; Ramsay NK; Arthur D; Verfaillie C; Miller J; Kersey J; McGlave P
Blood; 1996 Jul; 88(2):714-20. PubMed ID: 8695820
[TBL] [Abstract][Full Text] [Related]
6. Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry.
Giralt S; Szydlo R; Goldman JM; Veum-Stone J; Biggs JC; Herzig RH; Klein JP; McGlave PB; Schiller G; Gale RP; Rowlings PA; Horowitz MM
Blood; 2000 Jan; 95(2):410-5. PubMed ID: 10627443
[TBL] [Abstract][Full Text] [Related]
7. Trends in Late Mortality and Life Expectancy After Allogeneic Blood or Marrow Transplantation Over 4 Decades: A Blood or Marrow Transplant Survivor Study Report.
Bhatia S; Dai C; Landier W; Hageman L; Wu J; Schlichting E; Siler A; Funk E; Hicks J; Bosworth A; Te HS; Francisco L; Bhatia R; Salzman D; Goldman FD; Forman SJ; Weisdorf DJ; Wong FL; Arora M; Armenian SH
JAMA Oncol; 2021 Nov; 7(11):1626-1634. PubMed ID: 34499078
[TBL] [Abstract][Full Text] [Related]
8. Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update.
Brodsky I; Biggs JC; Szer J; Crilley P; Atkinson K; Downs K; Dodds A; Concannon AJ; Avalos BR; Tutschka P
Semin Oncol; 1993 Aug; 20(4 Suppl 4):27-31; quiz 32. PubMed ID: 8342072
[TBL] [Abstract][Full Text] [Related]
9. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Factors for Outcomes of Allogeneic HSCT for Children and Adolescents/Young Adults With CML in the TKI Era.
Shimada H; Tanizawa A; Kondo T; Nagamura-Inoue T; Yasui M; Tojo A; Muramatsu H; Eto T; Doki N; Tanaka M; Sato M; Noguchi M; Uchida N; Takahashi Y; Sakata N; Ichinohe T; Hashii Y; Kato K; Atsuta Y; Ohashi K;
Transplant Cell Ther; 2022 Jul; 28(7):376-389. PubMed ID: 35447373
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic bone marrow transplantation for chronic myeloid leukemia: a single center experience.
Vela-Ojeda J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; Rosas-Cabral A; Esparza MG; García-Chávez J; García-León LD; González-Llaven J
Arch Med Res; 2000; 31(2):206-9. PubMed ID: 10880729
[TBL] [Abstract][Full Text] [Related]
12. Case report of spontaneous remission of cytogenetic relapse of chronic myelogenous leukemia suggestive of progression to blast crisis after allogeneic bone marrow transplantation.
Agaliotis DP; Papenhausen PR; Moscinski LC; Elfenbein GJ
Ann Hematol; 1995 Jan; 70(1):37-41. PubMed ID: 7827205
[TBL] [Abstract][Full Text] [Related]
13. Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results.
Gaziev D; Galimberti M; Polchi P; Angelucci E; Giardini C; Baronciani D; Andreani M; Persini B; Erer B; Sodani P; Manna M; Nicolini G; Visani G; Lucarelli G;
Bone Marrow Transplant; 2002 Jan; 29(1):1-8. PubMed ID: 11840137
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia.
Reiter E; Greinix HT; Keil F; Brugger S; Rabitsch W; Schulenburg A; Mannhalter C; Schwarzinger I; Worel N; Volc-Platzer B; Fischer G; Dieckmann K; Hinterberger W; Schneider B; Haas OA; Geissler K; Kalhs P
Ann Hematol; 1999 Nov; 78(11):507-13. PubMed ID: 10602894
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood.
Holmqvist AS; Chen Y; Wu J; Battles K; Bhatia R; Francisco L; Hageman L; Kung M; Ness E; Parman M; Salzman D; Wadhwa A; Winther JF; Rosenthal J; Forman SJ; Weisdorf DJ; Armenian SH; Arora M; Bhatia S
JAMA Oncol; 2018 Dec; 4(12):e182453. PubMed ID: 30054602
[TBL] [Abstract][Full Text] [Related]
16. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia.
Huss R; Deeg HJ; Gooley T; Bryant E; Leisenring W; Clift R; Buckner CD; Martin P; Storb R; Appelbaum FR
Bone Marrow Transplant; 1996 Oct; 18(4):767-76. PubMed ID: 8899193
[TBL] [Abstract][Full Text] [Related]
17. Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation.
Jabro G; Koc Y; Boyle T; Schenkein DP; Ravalese J; Wazer D; Miller KB
Biol Blood Marrow Transplant; 1999; 5(3):173-9. PubMed ID: 10392963
[TBL] [Abstract][Full Text] [Related]
18. The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions?
Zeidner JF; Zahurak M; Rosner GL; Gocke CD; Jones RJ; Smith BD
Leuk Lymphoma; 2015 Jan; 56(1):128-34. PubMed ID: 24712979
[TBL] [Abstract][Full Text] [Related]
19. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group.
Arcese W; Goldman JM; D'Arcangelo E; Schattenberg A; Nardi A; Apperley JF; Frassoni F; Aversa F; Prentice HG; Ljungman P
Blood; 1993 Nov; 82(10):3211-9. PubMed ID: 7693042
[TBL] [Abstract][Full Text] [Related]
20. Late mortality after autologous blood or marrow transplantation in childhood: a Blood or Marrow Transplant Survivor Study-2 report.
Holmqvist AS; Chen Y; Wu J; Battles K; Bhatia R; Francisco L; Hageman L; Kung M; Ness E; Parman M; Salzman D; Winther JF; Rosenthal J; Forman SJ; Weisdorf DJ; Arora M; Armenian SH; Bhatia S
Blood; 2018 Jun; 131(24):2720-2729. PubMed ID: 29661789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
